À propos de la propriété intellectuelle Formation en propriété intellectuelle Respect de la propriété intellectuelle Sensibilisation à la propriété intellectuelle La propriété intellectuelle pour… Propriété intellectuelle et… Propriété intellectuelle et… Information relative aux brevets et à la technologie Information en matière de marques Information en matière de dessins et modèles industriels Information en matière d’indications géographiques Information en matière de protection des obtentions végétales (UPOV) Lois, traités et jugements dans le domaine de la propriété intellectuelle Ressources relatives à la propriété intellectuelle Rapports sur la propriété intellectuelle Protection des brevets Protection des marques Protection des dessins et modèles industriels Protection des indications géographiques Protection des obtentions végétales (UPOV) Règlement extrajudiciaire des litiges Solutions opérationnelles à l’intention des offices de propriété intellectuelle Paiement de services de propriété intellectuelle Décisions et négociations Coopération en matière de développement Appui à l’innovation Partenariats public-privé Outils et services en matière d’intelligence artificielle L’Organisation Travailler avec nous Responsabilité Brevets Marques Dessins et modèles industriels Indications géographiques Droit d’auteur Secrets d’affaires Académie de l’OMPI Ateliers et séminaires Application des droits de propriété intellectuelle WIPO ALERT Sensibilisation Journée mondiale de la propriété intellectuelle Magazine de l’OMPI Études de cas et exemples de réussite Actualités dans le domaine de la propriété intellectuelle Prix de l’OMPI Entreprises Universités Peuples autochtones Instances judiciaires Ressources génétiques, savoirs traditionnels et expressions culturelles traditionnelles Économie Financement Actifs incorporels Égalité des genres Santé mondiale Changement climatique Politique en matière de concurrence Objectifs de développement durable Technologies de pointe Applications mobiles Sport Tourisme PATENTSCOPE Analyse de brevets Classification internationale des brevets Programme ARDI – Recherche pour l’innovation Programme ASPI – Information spécialisée en matière de brevets Base de données mondiale sur les marques Madrid Monitor Base de données Article 6ter Express Classification de Nice Classification de Vienne Base de données mondiale sur les dessins et modèles Bulletin des dessins et modèles internationaux Base de données Hague Express Classification de Locarno Base de données Lisbon Express Base de données mondiale sur les marques relative aux indications géographiques Base de données PLUTO sur les variétés végétales Base de données GENIE Traités administrés par l’OMPI WIPO Lex – lois, traités et jugements en matière de propriété intellectuelle Normes de l’OMPI Statistiques de propriété intellectuelle WIPO Pearl (Terminologie) Publications de l’OMPI Profils nationaux Centre de connaissances de l’OMPI Série de rapports de l’OMPI consacrés aux tendances technologiques Indice mondial de l’innovation Rapport sur la propriété intellectuelle dans le monde PCT – Le système international des brevets ePCT Budapest – Le système international de dépôt des micro-organismes Madrid – Le système international des marques eMadrid Article 6ter (armoiries, drapeaux, emblèmes nationaux) La Haye – Le système international des dessins et modèles industriels eHague Lisbonne – Le système d’enregistrement international des indications géographiques eLisbon UPOV PRISMA UPOV e-PVP Administration UPOV e-PVP DUS Exchange Médiation Arbitrage Procédure d’expertise Litiges relatifs aux noms de domaine Accès centralisé aux résultats de la recherche et de l’examen (WIPO CASE) Service d’accès numérique aux documents de priorité (DAS) WIPO Pay Compte courant auprès de l’OMPI Assemblées de l’OMPI Comités permanents Calendrier des réunions WIPO Webcast Documents officiels de l’OMPI Plan d’action de l’OMPI pour le développement Assistance technique Institutions de formation en matière de propriété intellectuelle Mesures d’appui concernant la COVID-19 Stratégies nationales de propriété intellectuelle Assistance en matière d’élaboration des politiques et de formulation de la législation Pôle de coopération Centres d’appui à la technologie et à l’innovation (CATI) Transfert de technologie Programme d’aide aux inventeurs WIPO GREEN Initiative PAT-INFORMED de l’OMPI Consortium pour des livres accessibles L’OMPI pour les créateurs WIPO Translate Speech-to-Text Assistant de classification États membres Observateurs Directeur général Activités par unité administrative Bureaux extérieurs Avis de vacance d’emploi Achats Résultats et budget Rapports financiers Audit et supervision
Arabic English Spanish French Russian Chinese
Lois Traités Jugements Recherche par ressort juridique

Ordonnance administrative n° 169, série 2004, mettant en œuvre des directives pour l'utilisation exclusive de noms génériques ou de terminologies génériques dans toutes les ordonnances et commandes dans tous les établissements de la santé, Philippines

Retour
Version la plus récente dans WIPO Lex
Détails Détails Année de version 2004 Dates Adopté/e: 6 septembre 2004 Type de texte Textes règlementaires Sujet Brevets (Inventions), Marques, Noms commerciaux

Documents disponibles

Texte(s) principal(aux) Textes connexe(s)
Texte(s) princip(al)(aux) Texte(s) princip(al)(aux) Anglais Administrative Order No. 169, series of 2004, Implementing Guidelines for the Exclusive Use of Generic Names or Generic Terminology in all Prescriptions and Orders in all DOH Facilities        
 
Télécharger le PDF open_in_new
 Print 00000074 (4 pages)

•.

- ~-

,,Repub,.lic of the Philippines Department of Health

OFFICE OF THE SECRETARY

~ Trunk Line 743-83-Q1 (d Fax Line 743-18-29 Direct Line 711-95-02 to 03

06 September 2004

ADMINISTRATIVE ORDER No. 109 s.2004

Subject

I. Rationale

·Implementing Guidelines for the Exclusive Use of Generic Names or Generic Terminology in all Prescriptions and Orders in all DOH Facilities ·

Republic Act (RA) No. 6675 also known as the Generics Act of 1988 provides that it is the policy of the State to encourage the extensive use of drugs with generic names through a rational system of procurement and distribution.

Generic Name or Generic Terminology is the identification of drugs and medicines by their scientifically and internationally recognized active ingredients or by their official generic name.as determined by the Bureau of Food and Drugs of the Department of Health.

RA No. 6675 further provides that all government health agencies and their personnel as well as other government agencies shall use generic terminology or generic names in all transactions related to purchasing, prescribing, dispensing, and administering of drugs and medicines.

Administrative Order No. 51 series of 1988 entitled, "Implementing Guidelines for Department of Health Compliance with Republic Act 6675 (Generics Act of 1988)," provides that all prescriptions and orders and medicines in Department of Health (DOH) facilities shall be specified in generic terminology and that all written orders the generic name of the active ingredient shall be stated. Also stated in the said issuance is that while brand names may also be added, eventually all orders shall use generic names exclusively.

With the premises cited and relative preference and acceptability to generic drugs, this Order is crafted to assure the exclusive use of generic names sans the brand name from hereon.

® Departmem olHealth Sn112ki11g is hatz.&dew.s l() y()ur heedth Page I o.f'<J

·- '· .

II. Objectives

This Order is crafted to ensure that the following objectives are attained:

1) To provide guidelines in implementing the mandatory use of generic names in all DOH facilities and without the corresponding brand names.

2) To sustain the institutionalisation of promoting generic names and drugs by identifying the key personnel in the DOH and their corresponding roles and responsibilities.

3) To provide a system of monitoring compliance to generic prescription.

Ill. Applicability

This Order shall be applicable only to all DOH Facilities, which include Retained and Special Hospitals, Centers for Health Development, Service, Bureaus, Offices and Medical Centers, Sanitaria and all other units that are administratively and operationally under the control of the DOH.

IV. General Guidelines

1) All DOH facilities and their personnel shall only use generic names or terminology in all transactions related to procurement, prescribing, dispensing, and administering of drugs and medicines. This shall be inclusive of drugs, which are still covered with patent protection. The corresponding brand names of the drugs prescribed or ordered shall no longer be specified.

2) The Heads of the DOH facilities, i.e. Chiefs of Hospitals, Centers -for Health Development Directors, and others, shall act as the Head National Drug Policy Compliance Officer of their respective units and shall assign subordinate officers within their unit to assist or support them to ensure compliance with this Order and shall promulgate the corresponding issuance to implement and disseminate this Order.

3) Non-compliance to this Order shall be elevated by the concerned Heads of DOH Facilities to the Office of the Undersecretary, Project Executive Officer, Pharmaceutical Management Unit and the corresponding sanctions shall be imposed in accordance with RA 6675 and other applicable existing laws, rules and regulations.

® Department ~(Health Sn-wking is lwtzwdo«S to your hoolth Page 2 ~f't

.

. . •,

V. SPECIFIC GUIDELINES

A. Organizational Support Structure

1) The members and officers of the Therapeutics Committee of the Hospital or ttie Center for Health Development concerned as designated by their respective Heads of UniUOffice, in addition to their other roles and functions, shall serve as National Drug Policy Compliance Officers and shall provide staff work for routine and monitoring activities. They shall report directly to the Head of the National Drug Policy Compliance Officer at their office's level.

2) In the absence of a functional Therapeutics Committee, the Head of the DOH Facility concerned shall designate subordinate personnel to serve as National Drug Policy Compliance Officers.

3) All DOH Facilities shall establish a "Gamot Mabisa Abot-Kaya (GMA-50) Help Desk" to assist the public by providing access to low-cost essential drugs carried in its stock or by providing information on the relative availability of the demanded essential drugs through a referral system to other drug outlets of the Government and by providing other informational needs such as rational drug use. The GMA-50 Help Desk shall likewise be the central unit of the DOH Facility concerned with which public complaints shall be entertained and received. It shall be directly under the supervision of the Head of the DOH Facility.

4) All Nurses' Stations in DOH Hospitals must have an updated list of all available drugs carried in its stock or being sold by the hospital pharmacy. The physicians and nurses shall at all times exert diligence and prescribe the generically equivalent drugs that are carried in the hospital's stocks/pharmacy.

5} All DOH Facilities shall include in their work and financial plans, activities that will promote and strengthen the Generics Law and compliance with generic prescription. The minimum activities that can be undertaken, among others, shall include:

(a) Seminar/Training of new and old personnel to enhance awareness of the provisions of the Generics Law';

(b) Development and dissemination of Information, Education and Communication materials that will enhance public awareness on Generics Law and access to Generic Drugs by the public;

® Department '![Health Snwking is lwtz.w@w; lQ y&ur health Page 3 of4

·- " '' ' • .. . ~ .

(c) Establishment of the GMA-50 Help Desk; and (d) Yearly celebration of the Generics month.

B. Compliance Monitoring

1) The Head of the DOH Facility concerned shall submit a quarterly report (every three months, every second week of the month of April, July, October and January) to the Office of the Undersecretary, Project Executive Officer, Pharmaceutical Management Unit on all activities related to the Generics Law. Such shall include the list of personnel violating the Generics Law and non-compliance with Generic prescribing.

VI. Final Provisions

1) Separability Clause. If any provision of this Administrative Order is declared invalid or unconstitutional, the other provisions not affected thereby shall remain valid and subsisting.

2) Repealing Clause. Any provision of previous Orders and other related issuances inconsistent with those reflected in this are revised, accordingly modified and/or repealed.

3) Effectivity. This Order shall be effective immediately after publication in two (2) newspapers of general circulation.

® Department f!t'Heallh Smoking is; lutamdR!ws to yemr health Page4 ~(4


Aucune donnée disponible

N° WIPO Lex PH127